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Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease. Although the specific
mechanisms that dictate its biological aggressiveness are not clearly established, it is characterized
by a variety of molecular alterations as well as by the overexpression of mitogenic and angiogenic
growth factors and their receptors. PDACs also express high levels of vascular endothelial growth
factor (VEGF). Recent studies indicate that suppression of VEGF expression attenuates pancreatic
cancer cell tumorigenicity in a nude mouse model, and that VEGF can exert direct mitogenic effects
on some pancreatic cancer cells. These findings suggest that cancer cell derived VEGF promotes
pancreatic cancer growth in vivo via a paracrine angiogenic pathway and an autocrine mitogenic
pathway, and provide novel opportunities for therapeutic intervention in this deadly disease.
Carcinoma of the pancreas: An overview
Pancreatic ductal adenocarcinoma (PDAC) is responsible
for over 20% of deaths due to gastrointestinal malignan-
cies, making it the fourth most common cause of cancer
related mortality in the United States and other industri-
alized countries. The prognosis of patients with PDAC is
extremely poor, with overall 5-year survival rates that are
less than 1% [1], one-year overall survival of 12%, and a
median survival of 6 months [2]. Survival is often limited
to patients who had surgical resection at an early stage of
the disease. However, the diagnosis of PDAC is often es-
tablished at an advanced stage, precluding patients from
undergoing tumor resection in spite of limited results
with other treatment modalities [3]. These dismal statis-
tics are due to the tumor's propensity to metastasize when
small and undetectable, the advanced stage at which
many patients first develop symptoms, and the intrinsic
resistance of pancreatic cancer cells to cytotoxic agents
and radiotherapy [3–5]. PDAC may be an even more seri-
ous problem in the future since its incidence increases af-
ter age 50 and the general population world-wide is aging.
There is, therefore, an urgent need for an improved under-
standing of the mechanisms that contribute to pancreatic
tumor growth and metastasis, and for the design of thera-
pies for this disorder that are more effective than current
regimens. This review will cover in a brief manner the mo-
lecular biology of pancreatic cancer, and will then focus
on various aspects of vascular endothelial growth factors
in angiogenesis in general and in relation to PDAC in par-
ticular.
Molecular biology of pancreatic cancer
A plethora of genetic mutations have been described in
the cancer cells of PDAC patients. The most frequent alter-
ations (approximate frequency indicated in parenthesis)
include mutations in the K-ras oncogene (90%), the p53
(85%) and Smad4 (50%) tumor suppressor genes, and
the p16 (85% mutated and 15% silenced epigenetically)
cell cycle inhibitory gene [6,7]. Together, these alterations
promote cellular proliferation, suppress apoptotic path-
ways, and facilitate tumor spread and metastasis. In addi-
tion, there is overexpression of multiple tyrosine kinase
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receptors and their ligands which enhances mitogenesis,
and loss of responsiveness to the growth-inhibitory sig-
nals of members of the transforming growth factor beta
(TGF-β) family [6,7], which contribute in a significant
manner to the biological aggressiveness of PDAC.
It is well established that human pancreatic cancer cell
lines overexpress the epidermal growth factor (EGF) re-
ceptor (EGFR) and produce multiple ligands that bind di-
rectly to EGFR, including transforming growth factor-
alpha (TGF-α, amphiregulin, heparin-binding EGF-like
growth factor (HB-EGF), betacellulin and epiregulin [8–
12]. These cell lines also express other growth factors such
as fibroblast growth factors (FGFs) and platelet-derived
growth factor (PDGF) B chain [13–16]. However, expres-
sion of receptors and ligands in cell lines does not neces-
sarily indicate parallel alterations in PDAC in vivo.
Therefore, studies using human tissues have been of vital
importance in this regard. Studies using immunohisto-
chemistry, Northern blot analysis and in situ hybridiza-
tion techniques, have demonstrated that PDAC tissue
samples overexpress EGFR and six ligands that bind di-
rectly to EGFR (EGF, TGF-α, HB-EGF, betacellulin, epireg-
ulin and amphiregulin), as well as c-erb-B2, c-erb-B3, and
c-erb-B4 [10,11,17–19]. These cancers also overexpress
basic fibroblast growth factor (FGF-2), acidic FGF (FGF-
1), keratinocyte growth factor (KGF), FGF-5, PDGF B
chain (but not A chain), insulin-like growth factor-I (IGF-
I), the EGF-like growth factor Cripto, hepatocyte growth
factor (HGF), vascular endothelial growth factor (VEGF),
all 3 mammalian transforming growth factor beta (TGF-β)
isoforms, bone morphogenetic protein-2 (BMP-2) and ac-
tivin βA [14,15,20–29]. Many, but not all of the corre-
sponding receptors are concomitantly overexpressed. For
example, there is overexpression of PDGF receptor α and
β, the IGF-1 receptor, MET (the receptor that binds HGF),
the 2 Ig-like form of type I FGF receptor (FGFR-1), and the
type II TGF-β receptor (TβRII) but not the insulin receptor
[16,21,23,26,30–33]. IGF-II and insulin are not overex-
pressed in PDAC [21], whereas the type I TGF-β receptor
(TβRI) is under-expressed [31–33]. Thus, there is selective
overexpression of specific receptors and their ligands in
PDAC, and this concomitant overexpression leads to the
creation of aberrant paracrine and autocrine pathways
that confers a distinct growth advantage to pancreatic can-
cer cells.
The clinical importance of the above observations is un-
derscored by numerous observations. For example, the
concomitant presence in the cancer cells of EGFR and ei-
ther EGF or TGF-α is associated with disease progression
and decreased survival of PDAC patients [34]. Overexpres-
sion of c-erbB3 [19], FGF-2 [20] or TGF-β [35] is associat-
ed with decreased patient survival. The aberrant
cytoplasmic localization of amphiregulin [36] is also as-
sociated with decreased patient survival. Dominant nega-
tive inhibition of either EGFR or FGFR-1 markedly
attenuates pancreatic cancer cell growth [37–39]. Expres-
sion of a cyclin D1 antisense construct in pancreatic can-
cer cells lowers cyclin D1 levels in these cells, attenuates
their growth in vitro, and blocks their tumorigenicity in
vivo [40]. EGFR blockade with an anti-EGFR antibody at-
tenuates pancreatic tumor growth, and inhibition of EGFR
tyrosine kinase activity suppresses pancreatic tumor ang-
iogenesis [41,42]. Together, these findings are among
many that support the hypothesis that tyrosine kinase re-
ceptors and ligands have an important role in PDAC.
VEGF family of growth factors and their recep-
tors
VEGF-A, also called "vascular permeability factor", is a ho-
modimeric heparin-binding glycoprotein [43–45]. Five
major VEGF-A isoforms having 121, 145, 165, 189 and
206 amino acid residues, respectively, arise as a result of
alternative splicing from a single gene [46,47]. VEGF-A121
and VEGF-A145 are usually secreted while VEGF-A189 and
VEGF-A206 are almost completely sequestered in the extra-
cellular matrix [47]. VEGF-A165 is half secreted and half
bound to the cell surface and the extracellular matrix [48].
All 5 isoforms are mitogenic toward vascular endothelial
cells and induce vascular permeabilization. Additional
VEGF isoforms and VEGF-related genes have been identi-
fied, including VEGF-B [49,50], VEGF-C [51], VEGF-D
[52], VEGF-E [53] and placenta growth factor [54]. Direct
evidence for the role played by VEGF-A in embryonic vas-
culogenesis and angiogenesis was also demonstrated in
VEGF-A gene knockout studies [55,56], in which loss of a
single VEGF-A allele in mice resulted in embryonic lethali-
ty between day 11 and 12. Angiogenesis and blood-island
formation were impaired, resulting in severe developmen-
tal anomalies. This heterozygous lethal phenotype is in-
dicative of the tight dose-dependent regulation of
embryonic vessel development by VEGF-A [55,56]. VEGF-
A is also required for the cyclical blood vessel proliferation
in the female reproductive tract and for longitudinal bone
growth and endochondral bone formation in postnatal
development [43]. Together, these observations indicate
that VEGF-A has an important role in embryogenesis, de-
velopment, and tissue remodeling.
VEGF-A stimulates endothelial cell proliferation through
binding to two related tyrosine kinase receptors, VEGFR-1
(flt-1) VEGFR-2 (flk-1/KDR), on the surface of endothelial
cells, with most of the mitogenic effects taken to occur via
VEGFR-2 [57–59] (57–59). A third high affinity VEGF re-
ceptor, termed VEGFR-3 (Flt4), is expressed in lymphatic
vessels [60,61]. It is activated by VEGF-C, which can be
processed to a form that also binds to VEGFR-2 [57–61].
Furthermore, placenta growth factor and VEGF-B bind
only VEGFR-1, whereas VEGF-D, like VEGF-C, interactsMolecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/8
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with both VEGFR-2 and VEGFR-3 [57–61]. However,
VEGF-E binds only to VEGFR-2 [59]. All three VEGFRs are
class III transmembrane protein tyrosine kinases that pos-
sess seven immunoglobulin-like sequences in their extra-
cellular domains and a kinase insert in their intracellular
domains [57–61]. In addition, neuropilin-1 (Np-1), a
neuronal guidance molecule for axons in the developing
nervous system, also acts as a co-receptor for VEGF-A165
(but not for VEGF-A121), PlGF-2, VEGF-B and VEGF-E
[62]. Np-1 is a non-tyrosine kinase transmembrane pro-
tein whose overexpression in transgenic mice is associated
with various abnormalities, including excess capillary and
blood vessel formation [63]. The closely related neuropi-
lin-2 (Np-2) also binds VEGF-A165 (but not VEGF-A121),
as well as VEGF-A145 and PlGF-2, strongly implying that
both Np-1 and Np-2 in angiogenesis [62–64].
Gene knockout studies have shown that both VEGFR-1-/-
and VEGFR-2-/- mice die in utero between day 8.5 and 9.5
[65,66]. In VEGFR-1-/- mice, endothelial cells developed
in both embryonic and extra-embryonic sites but failed to
organize into normal vascular channels [65]. In VEGFR-2-
/- mice, hematopoietic precursors were severely reduced,
yolk-sac blood islands were absent, organized blood ves-
sels failed to develop throughout the embryo or the yolk
sac [66]. Furthermore, double knockouts for Np-1 and
Np-2 die in utero between day 8.5 and 9.5 [67]. They ex-
hibit avascular yolk sacs, and mice that are deficient for
Np-1 but heterozygous for Np-2, or deficient for Np-2 but
heterozygous for Np-1, die at day 10 to 10.5 and exhibit
diffuse vascular abnormalities that are more marked than
either Np-1 or Np-2 single knockouts [67]. Together, these
observations suggest that VEGFR-1 and VEGFR-2 are es-
sential for embryonic vasculature development, whereas
VEGFR-3 is essential for lymphangiogenesis, and that Np-
1 and Np-2 are as important as the other components of
the VEGF pathway in embryonic angiogenesis.
Angiogenesis in cancer
Tumor angiogenesis is often the consequence of an ang-
iogenic imbalance in which pro-angiogenic factors pre-
dominate over anti-angiogenic factors [68–71].
Furthermore, angiogenesis is essential for growth and me-
tastasis of most solid malignancies, and VEGF-A is be-
lieved to be critical for tumor angiogenesis [72,73]. Thus,
secretion of bioactive VEGF-A by cancer cells may be di-
rectly involved in tumor progression [43]. For example,
ovarian cancer cells secrete large amounts of bioactive
VEGF-A that may play a crucial role in the genesis of ascitic
fluid accumulation, angiogenesis and tumor induced im-
munosuppression in ovarian cancer patients [74]. In high
grade gliomas, bioactive VEGF-A secreted by the glioma
cells may account for the histopathological and clinical
features of these tumors, including such characteristics as
marked tumor angiogenesis and increased cerebral edema
[75,76].
VEGF-A is expression is induced by multiple mechanisms.
These include mutant K-ras and mutant p53, the von Hip-
pel Lindau gene product, growth factors such as FGF-2
and TGF-β, hypoxia, and transcription factors such as hy-
poxia inducible factor 1 alpha and SP1 [77–81]. VEGF-A
is up-regulated in many tumors including mammary,
colorectal, renal, liver, ovarian and gastric carcinomas and
gliomas [43], and its overexpression has been correlated
with poor prognosis. For example, breast cancer patients
with metastatic disease whose tumors exhibit increased
angiogenesis have a worse prognosis than the correspond-
ing patients whose tumors do not exhibit increased angio-
genesis [82]. Furthermore, suppression of VEGF-A
functions inhibits tumor growth in animal models as
demonstrated with a dominant negative VEGFR-2, solu-
ble VEGFR-1, neutralizing anti-VEGF-A antibody, VEGF-A
anti-sense expression, anti-VEGFR-1 or anti-VEGFR-2 ri-
bozymes, tyrosine kinase inhibitors of VEGFR-2, and anti-
VEGFR-2 antibodies [83–92].
Role of VEGF in pancreatic cancer angiogenesis
Although PDAC is not a grossly vascular tumor, this ma-
lignancy often exhibits enhanced foci of endothelial cell
proliferation. Moreover, several [24,93,94], but not all
[95] studies, have reported a positive correlation between
blood vessel density, tumor VEGF-A levels, and disease
progression in PDAC, raising the possibility that VEGF-A
may have an important role in this disease. However,
PDACs overexpress multiple additional mitogenic growth
factors which are also angiogenic (Table 1), such as EGF,
TGF-α, HGF, FGFs such as FGF-1, FGF-2, and FGF-5, and
PDGF-beta [6,96]. Therefore, while VEGF-A is of crucial
importance in promoting the growth and metastasis of
pancreatic cancer cells in PDAC, other factors are most
likely also involved in this process. Nonetheless, it has
been demonstrated that pancreatic cancer cells secrete bi-
ologically active VEGF-A [25], and the cancer cells in
PDAC as well as pancreatic cancer cell lines sometimes ex-
press VEGFR-1 and/or VEGFR-2 [97]. Moreover, some of
these cells may be growth stimulated by VEGF-A in cell
culture [97,98], and the major angiogenic agent toward
human dermal microvascular endothelial cells (HDMEC)
that is produced by T3M4 and PANC-1 human pancreatic
cancer cells is VEGF-A, since the mitogenic activity of con-
ditioned medium from these cells can be nearly complete-
ly suppressed by neutralizing anti-VEGF-A antibodies
[99]. Together, these observations suggest that by promot-
ing angiogenesis VEGF-A enhances tumor spread and me-
tastasis in this malignancy.
In support of the above conclusion, it has been demon-
strated that anti-angiogenic therapy is effective at sup-Molecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/8
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pressing tumor growth in animal models of PDAC. Thus,
the anti-angiogenic agent TNP-470 reduces neoangiogen-
esis in tumors formed by pancreatic cancer cell lines, and
decreases tumor growth and metastasis [99]. Suppression
of VEGF-A expression with a VEGF-A antisense construct
and with a VEGF directed ribozyme markedly attenuates
tumorigenicity in nude mice and formation of hepatic
metastases [25,100]. VEGF-A fused to diphtheria toxin
(DT-VEGF) internalizes in target cells via VEGFRs, inhibits
protein synthesis, and suppresses the growth of HUVEC
endothelial cells, thereby decreasing the volume and mi-
crovessel density in tumors formed by pancreatic cancer
cells [101]. Adenoviral vectors carrying sequences encod-
ing soluble VEGFR-1 and VEGFR-2 [102,103], or the VEG-
FR tyrosine kinase inhibitor PTK 787 [104], also inhibit
the growth of growth and/or metastasis of pancreatic can-
cers in mouse models. These findings underscore the im-
portance of the angiogenic process in PDAC, support the
hypothesis that VEGF-A exerts a crucial role in this regard,
and raise the possibility that VEGF-A may exert direct ef-
fects on pancreatic cancer cells in vivo.
VEGF-A can also act as a survival factor for endothelial
cells, rendering these cells more radioresistant [105]. It
can also promote the survival of leukemic cells, certain tu-
mor cells and hematopoietic stem cells [106–108]. In ad-
dition, VEGF-C is also overexpressed in PDAC, and this
overexpression has been correlated with enhanced lymph
node metastasis [109]. Thus, various members of the
VEGF family of ligands may contribute to the growth and
metastasis of pancreatic cancer cells through a variety of
mechanisms.
Additional mechanisms for promoting pancreat-
ic cancer angiogenesis
Although VEGF appears to be of paramount importance
for the angiogenic process in PDAC, these cancers express
many other pro-angiogenic factors (Table 1). As in the
case of VEGF, some of these growth factors activate tyro-
sine kinase receptors that are expressed in endothelial
cells within the pancreatic tumor mass, such as EGFR [17].
The importance of tyrosine kinase receptors other than
VEGFR in pancreatic cancer angiogenesis is underscored
by recent observations that inhibition of EGFR tyrosine ki-
nase activity suppresses pancreatic tumor angiogenesis
[42], and that NK4, an antagonist that is composed of the
N-terminal hairpin and subsequent four-kringle domains
of HGF, is a competitive antagonist for HGF that potently
inhibits angiogenesis in tumors formed by SUIT-2 pancre-
atic cancer cells [110].
Other pro-angiogenic factors that are overexpressed in
PDAC include certain chemokines such as Mip3α and in-
terleukin-8 (IL-8), which activate G-protein coupled re-
ceptors [111–113]. By contrast, TGF-βs activate serine-
threonine kinase receptors [114]. The importance of TGF-
βs are pro-angiogenic factors in PDAC is underscored by
the recent observation that expression of a soluble TβRII
in pancreatic cancer cells interferes with TGF-β actions, at-
tenuates tumor growth and metastasis, and suppresses tu-
mor angiogenesis [Rowland-Goldsmith, 2001 #905;
Rowland-Goldsmith MA, 2002 #2548].
Often, there is evidence for cross-talk between the various
angiogenic factors. For example, TGF-β1 and plasminogen
activator inhibitor-1 (PAI-1) are overexpressed in PDAC
[117,118], TGF-β1 induces PAI-1 expression in pancreatic
cancer cells [119], and both TGF-β1 and PAI-1 and can
promote angiogenesis in vivo [120–122]. TGF-βs are ini-
tially released as latent molecules that form complexes
with latent binding protein (LTBP), and their biological
effectiveness is dependent on their activation by such pro-
teins as plasmin, uPA and its receptor, the insulin-like
growth factor II (IGF-2) receptor, and tissue transglutami-
Table 1: Examples of Angiogenic Growth Factors that Are Overexpressed in Human Pancreatic Cancer and their Cognate Receptors
Growth Factors Activating Tyrosine Kinase Receptors Receptor
VEGF-A VEGFR-1 and VEGFR-2
VEGF-C VEGFR-3
EGF, TGF-α, HB-EGF EGF receptor
FGF-1, -2, -5 FGF receptors, types 1 and 2
PDGF B chain PDGF receptors α and β
IGF-1 IGF-1 receptor
Hepatocyte growth factor MET
Growth Factors that Activate Serine-Threonine Kinase Receptors
TGF-β1, -2, -3 Type II TGF-β receptor
Pro-Angiogenic Chemokines
IL-8 CXCR1 and CXCR2
Mip 3α CCR6Molecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/8
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nase [123,124]. The IGF-2 receptor, as well as uPA and its
receptor are overexpressed in PDAC [125,126], and pan-
creatic cancer cell lines express tissue transglutaminase
[127]. Furthermore, uPA and its receptor, as well as tissue
transglutaminase, have been implicated in the angiogenic
process [128,129], and the angiogenic potential of TGF-βs
may be enhanced by the presence of Smad4 mutations
[130], which are frequent in PDAC. uPA can transctivate
EGFR [131], and EGFR activation can induce the expres-
sion of VEGF and the pro-angiogenic chemokine inter-
leukin-8 [132,133]. Taken together, these observations
suggest that multiple pathways interact to enhance angio-
genesis in PDAC.
The pancreatic microenvironment may also serve to pro-
mote tumor angiogenesis [134]. In addition, as a conse-
quence of the existence of a continuous intra-pancreatic
portal circulation, pancreatic cancer cells may be exposed
to high levels of islet cell derived hormones such as insu-
lin and growth factors such as TGF-βs [135]. High insulin
levels bind and activate the IGF-1 receptor, which can
then promote angiogenesis [136,137]. Furthermore, islet
cell derived TGF-βs may enhance matrix metalloprotease-
9 (MMP-9) and VEGF expression in PDAC [31,138], and
suppress PTEN expression [139]. MMP-9 enhances tumor
angiogenesis [140] whereas PTEN, a phosphatase with
specificity for 3-phosphorylated inositol phospholipids,
has been implicated in the suppression of tumor angio-
genesis [141].
Conclusion
PDAC is a biologically aggressive malignancy that has a
propensity to spread locally and metastasize distally.
While not grossly vascular, these cancers exhibit foci of
micro-angiogenesis and overexpress multiple pro-ang-
iogenic factors. VEGF and related ligands represent a cru-
cial component of this pro-angiogenic switch, as
evidenced by the presence of high levels of VEGF in ascitic
fluid of PDAC patients [142], the correlation between
high serum VEGF levels and disease recurrence post-oper-
atively [143], and the observation that high VEGFR-2 lev-
els are associated with a worse prognosis in this disease
[144]. Therefore, mechanisms that target VEGF and the
various pathways that enhance the angiogenic process in
PDAC [145] may ultimately be of great therapeutic benefit
in patients with unresectable disease as well as following
surgery to prevent disease recurrence.
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